0
Signin
countryflagUS

18889881171

MSFT 425.025 -0.9035% AAPL 220.43 0.8648% NVDA 115.85 1.4004% GOOGL 172.44 -0.1101% GOOG 174.27 -0.0573% AMZN 182.99 1.1945% META 460.09 -0.2558% AVGO 152.64 0.859% TSLA 224.8499 4.102% TSM 161.61 1.1327% LLY 823.56 -4.2238% V 257.56 1.3338% JPM 209.535 0.453% UNH 562.83 0.5502% NVO 129.31 -1.7401% WMT 70.206 -0.5581% LVMUY 143.15 0.9022% XOM 116.85 1.5999% LVMHF 714.04 0.4982% MA 436.96 1.0429%

Eiger Biopharmaceuticals Inc

Healthcare US EIGR

2.6USD
2.60(-%)

Last update at 2024-05-08T13:30:00Z

Day Range

2.212.60
LowHigh

52 Week Range

0.202.98
LowHigh

Fundamentals

  • Previous Close -
  • Market Cap10.25M
  • Volume5723
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-83.35200M
  • Revenue TTM14.67M
  • Revenue Per Share TTM0.33
  • Gross Profit TTM 11.65M
  • Diluted EPS TTM-1.95

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -96.75300M -33.85300M -65.05100M -70.25200M -52.39100M
Minority interest - - - - -
Net income -96.77600M -33.91700M -68.63300M -73.64300M -52.39100M
Selling general administrative 29.11M 23.90M 20.56M 17.11M 13.96M
Selling and marketing expenses - - - - -
Gross profit 11.65M 11.40M - - 0.00000M
Reconciled depreciation 0.84M 0.80M 0.65M 0.49M 0.05M
Ebit -92.74000M -76.93900M -62.14900M -68.90400M -50.11600M
Ebitda -92.62100M -30.29400M -60.81200M -66.36000M -50.06200M
Depreciation and amortization 0.12M 46.65M 1.34M 2.54M 0.05M
Non operating income net other 0.12M 46.65M 0.69M 2.06M 0.98M
Operating income -92.74000M -76.93900M -62.14900M -68.90400M -51.04700M
Other operating expenses 106.22M 89.08M 62.15M 68.90M 51.05M
Interest expense 4.13M 3.56M 3.59M 3.41M 2.33M
Tax provision 0.02M 0.06M - - -
Interest income 1.08M 0.16M 0.70M 2.07M 1.00M
Net interest income -3.05000M -3.40100M -2.89000M -1.33300M -1.33200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.02M 0.06M 3.58M 3.39M 0.98M
Total revenue 13.48M 12.14M 0.00000M 0.00000M 0.00000M
Total operating expenses 104.39M 88.34M 62.15M 68.90M 51.05M
Cost of revenue 1.84M 0.74M - - 0.00000M
Total other income expense net -4.01300M 43.09M -2.90200M -1.34800M -0.01200M
Discontinued operations - - - - -
Net income from continuing ops -96.77600M -33.91700M -65.05100M -70.25200M -52.39100M
Net income applicable to common shares -96.77600M -33.91700M -65.05100M -70.25200M -52.39100M
Preferred stock and other adjustments - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 120.14M 126.40M 143.59M 105.14M 102.45M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 13.98M 9.36M 1.22M 5.39M 1.49M
Total liab 64.83M 54.00M 48.56M 48.66M 35.86M
Total stockholder equity 55.31M 72.40M 95.03M 56.48M 66.59M
Deferred long term liab - - - - -
Other current liab 15.65M 13.70M 11.40M 10.00M 4.19M
Common stock 0.04M 0.04M 0.03M 0.02M 0.02M
Capital stock 0.04M 0.04M 0.03M 0.02M 0.02M
Retained earnings -437.19300M -340.41700M -306.50000M -241.44900M -171.19700M
Other liab - - - - 0.21M
Good will - - - - -
Other assets 1.35M 4.51M 5.08M 2.51M 0.44M
Cash 25.80M 22.22M 28.86M 39.37M 61.26M
Cash and equivalents - - - - -
Total current liabilities 25.12M 29.90M 16.63M 16.95M 10.02M
Current deferred revenue - - - - -
Net debt 14.40M 10.32M 3.65M -7.12900M -35.64200M
Short term debt 0.49M 8.44M 0.58M 0.53M -
Short long term debt - 7.81M - - -
Short long term debt total 40.20M 32.54M 32.51M 32.24M 25.62M
Other stockholder equity 492.76M 412.93M 401.51M 297.86M 237.79M
Property plant equipment 0.70M 0.61M 0.71M 0.59M 0.17M
Total current assets 117.53M 103.36M 137.81M 100.38M 101.84M
Long term investments 0.00000M 17.26M - - -
Net tangible assets 55.31M 72.40M 95.03M 56.48M 66.59M
Short term investments 73.15M 66.59M 99.98M 55.62M 39.09M
Net receivables 1.75M 2.58M - - -
Long term debt 39.62M 23.99M 31.19M 30.39M 25.62M
Inventory 2.85M 2.61M 0.09M - -
Accounts payable 8.97M 7.76M 4.64M 6.41M 5.83M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.30000M -0.14900M -0.00800M 0.04M -0.02500M
Additional paid in capital - - - - -
Common stock total equity 0.04M 0.04M 0.03M 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity -437.19300M -340.41700M -306.50000M -241.44900M -171.19700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.35M 4.51M 3.90M 2.51M 0.44M
Deferred long term asset charges - - - - -
Non current assets total 2.60M 23.04M 5.79M 4.75M 0.60M
Capital lease obligations 0.57M 0.74M 1.32M 1.85M -
Long term debt total 39.62M 23.99M 31.19M 30.39M 25.62M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 9.97M 14.98M -44.52900M -15.99600M -28.94300M
Change to liabilities 3.11M 5.54M -0.40800M 6.19M 4.97M
Total cashflows from investing activities 9.63M 61.53M -44.78700M -16.47100M -29.08500M
Net borrowings 5.45M -0.17500M 6.56M 4.96M 9.94M
Total cash from financing activities 76.95M 3.17M 97.46M 58.20M 100.98M
Change to operating activities -0.13200M 0.42M -3.99800M -0.59300M 1.42M
Net income -96.77600M -33.91700M -65.05100M -70.25200M -52.39100M
Change in cash 3.58M -6.64300M -10.50900M -21.88900M 29.23M
Begin period cash flow 22.22M 28.86M 39.37M 61.26M 32.03M
End period cash flow 25.80M 22.22M 28.86M 39.37M 61.26M
Total cash from operating activities -83.01000M -71.34200M -63.18500M -63.61400M -42.67100M
Issuance of capital stock 71.40M 3.04M 96.78M 53.19M 90.64M
Depreciation 0.84M 0.80M 0.65M 0.49M 0.05M
Other cashflows from investing activities - 46.77M 46.49M -15.99600M -28.94300M
Dividends paid - - - -0.13000M -
Change to inventory -1.36700M -2.42400M -2.42400M -2.42400M -2.42400M
Change to account receivables 0.83M -2.57600M -2.57600M -2.57600M -2.57600M
Sale purchase of stock 0.16M 0.26M 0.19M 0.13M 0.43M
Other cashflows from financing activities 38.67M -0.13000M 0.50M 6.67M 9.91M
Change to netincome 10.52M 8.12M 6.19M 5.91M 5.01M
Capital expenditures 0.34M 48.73M 0.26M 0.47M 0.14M
Change receivables 0.83M -2.57600M - - -
Cash flows other operating -1.53900M -48.13500M -5.01100M -5.78500M -0.47600M
Exchange rate changes - - - - -
Cash and cash equivalents changes 3.58M -6.64300M -10.50900M -21.88900M 29.23M
Change in working capital 0.48M -1.34100M -5.89700M -0.00900M 4.07M
Stock based compensation 8.32M 7.90M 5.97M 5.68M 5.01M
Other non cash items 4.13M 0.71M 1.02M 0.95M 1.02M
Free cash flow -83.35000M -120.07400M -63.44300M -64.08900M -42.81300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EIGR
Eiger Biopharmaceuticals Inc		 2.60 -% 2.60 - - 0.70 0.87 0.81 -0.1465
NVO
Novo Nordisk A/S		 -2.29 1.74% 129.31 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 3.80 2.90% 135.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.67 0.75% 494.48 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 22.92 2.16% 1083.78 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.

Eiger Biopharmaceuticals Inc

2155 Park Boulevard, Palo Alto, CA, United States, 94306

Key Executives

Name Title Year Born
Mr. David A. Cory M.B.A., MBA, R.Ph, R.Ph. Bus. Founder, Pres, CEO & Director 1964
Dr. Jeffrey S. Glenn M.D., Ph.D. Scientific Founder & Independent Director 1963
Mr. Sriram Ryali M.B.A. Chief Financial Officer 1981
Mr. Eldon C. Mayer III, M.B.A. Exec. VP & Chief Commercial Officer 1961
Mr. Christopher A. Kurtz Chief Technical Officer 1967
Mr. Erik Atkisson Gen. Counsel, Corp. Sec. & Chief Compliance Officer 1972
Dr. Ingrid C. Choong Sr. VP of Clinical Devel. NA
Dr. Stephana E. Patton J.D., Ph.D. Consultant 1971
Mr. Rich Franco M.B.A. Sr. VP of Regulatory Affairs NA
Dr. Colin Hislop M.D. Sr. VP of Clinical & Devel. Operations 1958

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.